News Roche's Tecentriq hits trouble with NICE in bladder cancer Cancer Drugs Fund could cover costs in first line use.
News Teva's Cinqaero to challenge Nucala after clearing NICE Discount swings NICE decision, drug will compete with GSK rival
News Disappointment as government delays pharma-friendly policies Proposals fall short of ambitions of Accelerated Access Review.
News Alexion price cut opens up Strensiq to more patients Managed access scheme will control costs to NHS.
News Pfizer facing NICE showdown over leukaemia drug Pfizer locks horns with NICE following EU approval.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
